BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 1494808)

  • 1. Favorable response of metastatic adrenocortical carcinoma to etoposide, adriamycin and cisplatin (EAP) chemotherapy. Report of two cases.
    Berruti A; Terzolo M; Paccotti P; Veglio F; Pia A; Dogliotti L; Angeli A
    Tumori; 1992 Oct; 78(5):345-8. PubMed ID: 1494808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
    Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
    Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression.
    Zancanella P; Pianovski MA; Oliveira BH; Ferman S; Piovezan GC; Lichtvan LL; Voss SZ; Stinghen ST; Callefe LG; Parise GA; Santana MH; Figueiredo BC
    J Pediatr Hematol Oncol; 2006 Aug; 28(8):513-24. PubMed ID: 16912591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.
    Fassnacht M; Dekkers OM; Else T; Baudin E; Berruti A; de Krijger R; Haak HR; Mihai R; Assie G; Terzolo M
    Eur J Endocrinol; 2018 Oct; 179(4):G1-G46. PubMed ID: 30299884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial.
    Berruti A; Terzolo M; Sperone P; Pia A; Della Casa S; Gross DJ; Carnaghi C; Casali P; Porpiglia F; Mantero F; Reimondo G; Angeli A; Dogliotti L
    Endocr Relat Cancer; 2005 Sep; 12(3):657-66. PubMed ID: 16172198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility of the association of mitotane with etoposide, adriamycin and cisplatin combination chemotherapy in advanced adrenocortical cancer patients. Report on 7 cases.
    Pia A; Berruti A; Terzolo M; Paccotti P; Letizia C; Dogliotti L; Angeli A
    Ann Oncol; 1995 May; 6(5):509-10. PubMed ID: 7669716
    [No Abstract]   [Full Text] [Related]  

  • 7. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
    Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
    Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic chemotherapy for adrenocortical carcinoma.
    Dogliotti L; Berruti A; Pia A; Paccotti P; Alì A; Angeli A
    Minerva Endocrinol; 1995 Mar; 20(1):105-9. PubMed ID: 7544429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A Case Report of a Patient with Metastatic Adrenocortical Carcinoma who Received the Combination Etoposide, Doxorubicin, Cisplatin, and Mitotane Therapy and Achieved Remission].
    Ueda S; Nakane K; Namiki S; Takeuchi Y; Kawase M; Takeuchi S; Kawase K; Nakai C; Kato D; Takai M; Iinuma K; Tsuchiya T; Miyazaki T; Koie T
    Hinyokika Kiyo; 2022 May; 68(5):139-143. PubMed ID: 35748231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term disease free survival in a patient with metastatic adreno-cortical carcinoma after complete pathological response to chemotherapy plus mitotane.
    Sperone P; Berruti A; Gorzegno G; Paccotti P; Terzolo M; Porpiglia F; Angeli A; Dogliotti L
    J Endocrinol Invest; 2006 Jun; 29(6):560-2. PubMed ID: 16840836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study.
    Williamson SK; Lew D; Miller GJ; Balcerzak SP; Baker LH; Crawford ED
    Cancer; 2000 Mar; 88(5):1159-65. PubMed ID: 10699907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma.
    Bonacci R; Gigliotti A; Baudin E; Wion-Barbot N; Emy P; Bonnay M; Cailleux AF; Nakib I; Schlumberger M;
    Br J Cancer; 1998 Aug; 78(4):546-9. PubMed ID: 9716042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination chemotherapy in advanced adrenocortical carcinoma.
    Fassnacht M; Terzolo M; Allolio B; Baudin E; Haak H; Berruti A; Welin S; Schade-Brittinger C; Lacroix A; Jarzab B; Sorbye H; Torpy DJ; Stepan V; Schteingart DE; Arlt W; Kroiss M; Leboulleux S; Sperone P; Sundin A; Hermsen I; Hahner S; Willenberg HS; Tabarin A; Quinkler M; de la Fouchardière C; Schlumberger M; Mantero F; Weismann D; Beuschlein F; Gelderblom H; Wilmink H; Sender M; Edgerly M; Kenn W; Fojo T; Müller HH; Skogseid B;
    N Engl J Med; 2012 Jun; 366(23):2189-97. PubMed ID: 22551107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of metastatic adrenal cortical carcinoma with cisplatin and etoposide (VP-16).
    Johnson DH; Greco FA
    Cancer; 1986 Nov; 58(10):2198-202. PubMed ID: 3756767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case Report: Exceptional Response to Second Line Temozolomide Therapy in a Patient With Metastatic Adrenocortical Carcinoma.
    Cosentini D; Turla A; Carminati O; Grisanti S; Ferrari VD; Laganà M; Rosti G; Sigala S; Berruti A
    Front Endocrinol (Lausanne); 2021; 12():674039. PubMed ID: 33967965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: a single institute experience.
    Uchihara M; Tanioka M; Kojima Y; Nishikawa T; Sudo K; Shimoi T; Noguchi E; Maeshima AM; Yonemori K
    Int J Clin Oncol; 2021 Dec; 26(12):2275-2281. PubMed ID: 34468885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer.
    Roca E; Berruti A; Sbiera S; Rapa I; Oneda E; Sperone P; Ronchi CL; Ferrari L; Grisanti S; Germano A; Zaggia B; Scagliotti GV; Fassnacht M; Volante M; Terzolo M; Papotti M
    Endocr Relat Cancer; 2017 Jul; 24(7):319-327. PubMed ID: 28432084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
    Hantel C; Jung S; Mussack T; Reincke M; Beuschlein F
    Endocr Relat Cancer; 2014 Jun; 21(3):383-94. PubMed ID: 24532475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of metastatic adrenal cortical carcinoma with etoposide (VP-16) and cisplatin after failure with o,p'DDD. Clinical case reports.
    Zidan J; Shpendler M; Robinson E
    Am J Clin Oncol; 1996 Jun; 19(3):229-31. PubMed ID: 8638530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastatic adrenocortical carcinoma presenting simultaneously with Cushing's and Conn's syndromes: a case report.
    Beom SH; Lee KW; Yang Y; Choi Y; Song KH; Kim YJ; Kim JH; Bang SM; Chung JH; Lee JS
    Jpn J Clin Oncol; 2011 Nov; 41(11):1287-91. PubMed ID: 21980052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.